Number of Clinical Trials Using Cannabis-Based Medicines to Treat Symptoms From Conditions Like Cancer Increases by 650% Since 2010, Report Finds

Ryan Allway

August 31st, 2023

News, Top News

Key Findings:

Pain, from various conditions, is by far the most prevalent symptom treated in clinical trials involving cannabinoids – with pain being the target condition in 46% of trials since 2010.
The most commonly featured conditions in the patent landscape include epilepsy, cancer and associated conditions, seizures, and autism spectrum disorder.
Clinical trials featuring patented compounds (Sativex and Epidiolex) dominate completed phase 3 trials
It is estimated that global sales within the pharmaceutical cannabis industry will amount to approximately US$1.11 billion in 2023, with projections indicating a growth to US$1.37 billion by 2027.

The number of clinical trials using cannabis-based medicines to treat patients with symptoms from a variety of conditions – including cancer, epilepsy and autism spectrum disorder – has exploded since 2010, a new report has found.

In 2010, only eight clinical trials globally used cannabis-based medicines as a treatment for conditions such as Diabetes and Anxiety. In 2022 alone, 60 clinical trials began – a 650% increase in comparison to 2010.

So far this year, 49 clinical trials involving cannabis-based medicines have already started, with more due to kick-off before the end of the year.

Almost every year since 2015, the number of clinical trials has increased year-on-year.

Almost half of all clinical trials globally involving pharmaceutical cannabis medicines since 2010 have targeted ‘pain’ from various conditions.

Of the 440 clinical trials analysed, in 46% – or 202 trials in total – ‘pain’ was found to be the target condition for treatment. Chronic or neuropathic pain, in particular, has been the target symptom in the majority of trials, encompassing conditions such as fibromyalgia/myofascial pain, cancer-related pain and pain associated with neurodegenerative diseases such as MS and Parkinson’s.

In recent years, there has, instead, been a notable increase in clinical trials examining the potential benefits of cannabis and cannabinoids for various mental-related disorders, such as anxiety and depression.

The types of medicines being used in these clinical trials consist of a variety of different cannabinoids. Of all trials analysed, 34.5% used a combination of the two most commonly-known cannabinoids – THC and CBD.

Lawrence Purkiss, senior analyst at Prohibition Partners and co-author of the report, said: “Looking at the development of clinical trials in cannabis over the last decade gives great insight into the potential breakthroughs in the space in the coming years. From analysing the patent landscape in conjunction with the clinical trials record, it’s clear that the possibilities for further cannabinoid-based treatments are incredibly broad, with significant interest already in specific areas.”

Analysis and findings have been published this week by Prohibition Partners in The Pharmaceutical Cannabis Report: 3rd Edition, in collaboration with Cannabiscientia, just hours before the US Department of Health and Human Services (HHS) sent a recommendation to the Drug Enforcement Administration (DEA), stating that cannabis should be reclassified from Schedule I to Schedule III – potentially paving the way for many more patients to benefit from cannabis-based medicines.

On the HHS’s recommendation, Stephen Murphy, CEO of Prohibition Partners, said: “The HHS recommendation further splits the path of cannabis between adult-use and medical purposes. This helps advance access, but also opens the door for the existing healthcare and pharmaceutical industry to embrace patient demand.”

“The just-published The Pharmaceutical Cannabis Report: 3rd Edition highlights the path forward for cannabis and the explosion of clinical research and development that will be further enhanced once this recommendation comes to fruition.”

ABOUT PROHIBITION PARTNERS

Prohibition Partners is a data, media and tech company operating in the fast-growing legal cannabis industry. We provide the industry with specialist information, data analytics and digital commerce solutions.

For additional comment, more information about the report or visualisations of data, please contact Mike Hoban – michael@prohibitionpartners.com

Michael Hoban

Head of Marketing & Comms

31 New Inn Yard, London, EC2A 3EY

+44 (0)7841 697433

prohibitionpartners.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Search CannabisFN

Press Coverage

Psychedelics Index

Visit the CFN Video Library

Join Our Facebook Page

Top Videos

Neill Dixon of O’Cannabiz Conference & Expo

The producers of O’ Cannabiz have decades of experience producing national-profile events and creating global connections between business communities in the arts, broadcasting, media and technology. They have organized trade summit initiatives with governments around the world. And they have worked closely with sponsors in all levels of Canadian government.

Alan Brochstein of 420 Investor

Alan Brochstein’s 420 Investor is the go-to community for investors to learn, explore, and profit from the marijuana companies. The main goal of 420 Investor is to provide real-time, objective information about the top marijuana companies in the market in order to help investors capitalize on cannabis.

Xtraction Services

Xtraction Services provides state-of-the-art, fully-automated, supercritical CO2 extraction machines with on-site staffing at no upfront cost, and a simple volume-based pricing model.

Pivot Pharmaceuticals Inc.

Pivot Pharmaceuticals Inc. is an emerging biopharmaceutical company engaged in the development and commercialization of therapeutic pharmaceuticals and nutraceuticals.

Network Partners

Follow Us on Social Media

Facebook

Twitter

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.